semaglutide new england journal of medicine Cardiac Trials | ~~ Most popular trial post #2023 ~~ GLP1 agonism in overweight/obese patients to reduce cardiovascular mortality? This landmark trial Happy to share the publication

Weight loss must always be combined with a healthy diet and exercise to lower the risk for long-term health problems

The microbial metabolite trimethylamine N-oxide promotes antitumor immunity in triple-negative breast cancer

Wegovy (semaglutide) tablets are a prescription medicine used with a reduced-calorie diet and increased physical activity to: reduce the risk of major cardiovascular events such as death, heart attack, or stroke in adults with known heart disease and with either obesity or overweight

In response to food ingestion, L cells secrete hormones [77], such as glucagon-like peptide-1 (GLP-1) and peptide YY (PYY)